Ana Callejo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Callejo has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Marie Clasina Dingemans
Department of Respiratory Medicine, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands
3 shared publications - Bartosz Wasag
Medical University of Gdansk, Gdansk, Poland
2 shared publications - Jordi Remon
Department of Cancer Medicine, Gustave Roussy, Villejuif, France
2 shared publications - Julien Mazieres
Pulmonology Department, Toulouse University Hospital and Centre de Recherche Cancérologie Toulouse CRCT, INSERM, Toulouse, France
2 shared publications - Kamal Al-Rabi
Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan
2 shared publications - Noemi Reguart
Hospital Clinic, Barcelona, Spain
2 shared publications
Latest Publications
- 21 April 2025
- Published by Elsevier in Lung Cancer
- Vol. 204, 108553
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial
- 21 April 2025
- Published by Elsevier in Lung Cancer
- Vol. 204, 108553
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial
- 20 April 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (12) , 1350-1356
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Osimertinib has been established as a standard of care for patients with common sensitizing EGFR-mutant advanced non–small-cell lung cancer (NSCLC) although the sequential approach (first-generation inhibitor gefitinib followed by osimertinib) has not been formally compared. The phase II APPLE trial (ClinicalTrials.gov identifier: NCT02856893 ) enrolled 156 treatment-naïve patients, and two treatment strategies were evaluated: osimertinib up front or the sequential treatment approach with gefitinib up front followed by osimertinib at the time of progression, either molecular progression (detection of plasma T790M resistance mutation) regardless of the radiologic status or just at the time of radiologic progression. Patients' characteristics were well balanced, except for the higher proportion of baseline brain metastases in the sequential approach (29% v 19%). Per protocol, 73% of patients switched to osimertinib in the sequential arm. Up-front treatment with osimertinib was associated with a lower risk of brain progression versus the sequential approach (hazard ratio [HR], 0.54 [90% CI, 0.34 to 0.86]), but a comparable overall survival was observed between both strategies (HR, 1.01 [90% CI, 0.61 to 1.68]), with the 18-month survival probability of 84% and 82.3%, respectively. The APPLE trial suggests that a sequential treatment approach is associated with more frequent progression in the brain but a similar survival in advanced EGFR-mutant NSCLC.
- 20 April 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (12) , 1350-1356
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Osimertinib has been established as a standard of care for patients with common sensitizing EGFR-mutant advanced non–small-cell lung cancer (NSCLC) although the sequential approach (first-generation inhibitor gefitinib followed by osimertinib) has not been formally compared. The phase II APPLE trial (ClinicalTrials.gov identifier: NCT02856893 ) enrolled 156 treatment-naïve patients, and two treatment strategies were evaluated: osimertinib up front or the sequential treatment approach with gefitinib up front followed by osimertinib at the time of progression, either molecular progression (detection of plasma T790M resistance mutation) regardless of the radiologic status or just at the time of radiologic progression. Patients' characteristics were well balanced, except for the higher proportion of baseline brain metastases in the sequential approach (29% v 19%). Per protocol, 73% of patients switched to osimertinib in the sequential arm. Up-front treatment with osimertinib was associated with a lower risk of brain progression versus the sequential approach (hazard ratio [HR], 0.54 [90% CI, 0.34 to 0.86]), but a comparable overall survival was observed between both strategies (HR, 1.01 [90% CI, 0.61 to 1.68]), with the 18-month survival probability of 84% and 82.3%, respectively. The APPLE trial suggests that a sequential treatment approach is associated with more frequent progression in the brain but a similar survival in advanced EGFR-mutant NSCLC.
- 28 April 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34 (5)
Table of Contents
- 26 February 2022
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 100, 33-45
Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence
- 26 February 2022
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 100, 33-45
Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence
- 6 January 2022
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 122 (3) , 823-825
Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay
- 6 January 2022
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 122 (3) , 823-825
Herpes simplex encephalitis in the context of immune checkpoint inhibitors: a complex interplay
- Open Access
- 8 December 2021
- Published by Springer Nature in Research Square
Longitudinal Evolution of Cognitive Function in Colorectal and Breast Cancer Survivors Treated with (Neo)Adjuvant Chemotherapy.
Introduction & objectives: Advances in early diagnosis and treatment are improving the long-term survival of patients with cancer. Cancer-related cognitive impairment (CRCI) is often reported as a long-term chemotherapy sequel. Improving the knowledge of CRCI may help to prevent, manage and identify risk factors. Our main goal is to assess the cognitive function evolution and determine the potential influence of chemotherapy in neurological decline. Material and methods We designed a prospective and longitudinal study of a colorectal and breast cancer patient cohort (n=62) and we assessed cognitive function evolution using a battery of 11 neuropsychological tests at three time points: baseline, post chemotherapy and 6 months after finishing chemotherapy. Sociodemographic features, quality of life, anxiety and depression status were recorded as well as their interplay with cognitive evolution. Results At baseline, 14.5% of the patients had cognitive dysfunction. Older age, low level of education, colorectal cancer and comorbidities were associated to initial cognitive damage. A total of 61.9% of patients presented a decline of scores in 4 or more tests from baseline to post chemotherapy assessment. This percentage decreased to 24.4% in the late follow up evaluation, showing an intra-patient recovery after chemotherapy. Verbal and visual memory is the domain most affected. Conclusion Our data suggest that cognitive function of cancer patients treated with chemotherapy may subtly but transiently decline during treatment, with most patients recovering their cognitive function over time. Further research is needed in this field as CRCI continues to impact on quality of life and mental well-being.
- 8 December 2021
- Published by Springer Nature in Research Square
Open AccessLongitudinal Evolution of Cognitive Function in Colorectal and Breast Cancer Survivors Treated with (Neo)Adjuvant Chemotherapy.
Introduction & objectives: Advances in early diagnosis and treatment are improving the long-term survival of patients with cancer. Cancer-related cognitive impairment (CRCI) is often reported as a long-term chemotherapy sequel. Improving the knowledge of CRCI may help to prevent, manage and identify risk factors. Our main goal is to assess the cognitive function evolution and determine the potential influence of chemotherapy in neurological decline. Material and methods We designed a prospective and longitudinal study of a colorectal and breast cancer patient cohort (n=62) and we assessed cognitive function evolution using a battery of 11 neuropsychological tests at three time points: baseline, post chemotherapy and 6 months after finishing chemotherapy. Sociodemographic features, quality of life, anxiety and depression status were recorded as well as their interplay with cognitive evolution. Results At baseline, 14.5% of the patients had cognitive dysfunction. Older age, low level of education, colorectal cancer and comorbidities were associated to initial cognitive damage. A total of 61.9% of patients presented a decline of scores in 4 or more tests from baseline to post chemotherapy assessment. This percentage decreased to 24.4% in the late follow up evaluation, showing an intra-patient recovery after chemotherapy. Verbal and visual memory is the domain most affected. Conclusion Our data suggest that cognitive function of cancer patients treated with chemotherapy may subtly but transiently decline during treatment, with most patients recovering their cognitive function over time. Further research is needed in this field as CRCI continues to impact on quality of life and mental well-being.
- 1 August 2001
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 31 (8) , 1250-1255
Early introduction of cereals into children's diets as a risk‐factor for grass pollen asthma
Background The prevalence of asthma has increased from the 1950s to the 1990s. The relationship between diet and asthma is an area of controversy that has never been fully evaluated. Attempts at diet...
- 1 August 2001
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 31 (8) , 1250-1255
Early introduction of cereals into children's diets as a risk‐factor for grass pollen asthma
Background The prevalence of asthma has increased from the 1950s to the 1990s. The relationship between diet and asthma is an area of controversy that has never been fully evaluated. Attempts at diet...